Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 17/09/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ✅ P/E passed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -25.64%
Price change 2019 → 2020: 13.60%
Price change 2020 → 2021: -13.54%
Price change 2021 → 2022: 41.82%
Price change 2022 → 2023: -20.67%
Price change 2023 → 2024: -33.37%
Price change 2024 → 2025: 13.06%
Price change 2025 → 2026: -14.85%
Price change 2026 (year to date): -14.29%
Financial growth
Revenue CAGR (8 years): -2.64%
Earnings CAGR (8 years): -7.76%
Growth status: weak or negative trend (<1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.08
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 13.06
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 11.03% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="BOI.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Boiron S.A. | 11.9 | 0.08 | −0.2 % | 🔒 |
| LNA Santé S.A. | 9.5 | 2.75 | +10.4 % | – |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Equasens S.A. | 11.3 | 0.21 | +6.5 % | – |
| Lumibird S.A. | 37.3 | 0.71 | +9.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|